28th Sep 2006 14:59
Vectura Group PLC28 September 2006 Vectura Group plc Annual General Meeting Chippenham, UK, 28 September 2006 - Vectura Group plc (LSE: VEC) confirms thatall resolutions put to the Annual General Meeting on 27 September were dulypassed. Enquiries: Vectura Group plc Tel+ 44(0) 1249 667700Chris Blackwell, Chief ExecutiveAnne Hyland, CFO Financial Dynamics Tel: +44(0) 20 7831 3113Sarah MacLeod / John Gilbert Notes for Editors About Vectura Vectura's principal focus is the development of a range of inhaled drugs for thetreatment both of lung diseases and other conditions where optimised deliveryvia the lungs can provide significant benefits, such as a rapid onset of action,improved efficacy and improved tolerability compared with current therapies. Vectura's products combine its proprietary, innovative, pulmonary formulationand device technologies (Aspirair(R) GyroHaler(R) and PowderHale(R)) withexisting, off-patent drugs either for use in new indications or to provideinhalation as an improved route of administration. Using drugs that have alreadybeen approved in some form in at least one major pharmaceutical market lowersthe risk of product development failure compared to new chemical entities,Vectura is able to secure patent protection for its portfolio by identifying newindications for off-patent compounds and applying the Company's proprietarydelivery technologies to create new methods of administration. The Company hasdevelopment collaborations with a number of companies, including BoehringerIngelheim, Novartis, GSK and Chiesi and an un-named leading internationalpharmaceutical company. For further information, please visit Vectura's website at www.vectura.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
VEC.L